Many health care professionals are faced with patients who have symptoms of Fibromyalgia, yet few practitioners have training in the diagnosis and management of this disease. With news of promising therapies come questions from the general medical, rheumatologic, and managed care community. What clinical benefits does this therapy offer? What role does this therapy have in delivering increased value and improved patient outcomes? Can this therapy be evaluated through an evidenced-based approach?

Target Audience:

This activity has been designed to meet the educational needs of physicians, nurses, Physician Assistants, Nurse Practitioners, and other health care professionals who are interested in identifying patients with Fibromyalgia as well as disease management programs for Fibromyalgia patients.

ProgramObjectives:

After completing this activity, the participant should be better able to:

Understand the challenges in diagnosis and treatment of Fibromyalgia

Cite and potentially apply available and emerging therapies, treatment regimens, and their durations

Understand alternative and complementary therapies available to the patient

AAFP Accreditation Statement

Physicians:

This program has been reviewed and is acceptable for up to 1 Prescribed credit hours by The American Academy of Family Physicians. AAFP Prescribed credit is accepted by The AMA as equivalent to AMA PRA Category I for AMA The Physicians' Recognition Award. When applying for the AMA PRA, Prescribed hours earned must be reported as Prescribed hours, not as Category I. (This statement applies to all Physicians, not just Family Physicians).

Faculty Disclosure and resolution of COI: As an provider of continuing medical education, it is the policy of ScientiaCME and Educational Review Systems (ERS) to ensure balance, independence, objectivity, and scientific rigor in all of its educational programs. In accordance with this policy, faculty must disclose to the participants any significant relationships with the commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this continuing pharmaceutical education program. The intent of this disclosure is not to prevent a person with a significant financial or other relationship from participating in the planning or review of programs, but rather to provide the intended audience with information on which they can make their own judgments. It remains for the audience to determine whether the interests or relationships of planning committee members, reviewers, or cosponsors may influence the presentation with regard to exposition or conclusion.

Faculty Disclosure: Chad S. Boomershine, MD, PhD discloses that he (or his spouse) has a financial interest or other financial relationship with the manufacturer(s) of products or providers of services discussed in the presentation. He has consulting agreements, has received honoraria, and is a member is of the Speaker's Bureau of: Forest Pharmaceuticals Inc., Pfizer, Inc., Eli Lily & Co., and Takeda Pharmaceuticals America, Inc. He has also received research grants from Pfizer, Inc.

Disclosures of Educational Planners: Steven Sachse is an officer and part owner of ScientiaCME, LLC. ScientiaCME has received grants from Bayer, Edwards Lifesciences, Eisai, Daiichi-Sankyo, Lilly, Merck, Pfizer, Sanofi Aventis, Wolf-Torey Medical, and currently has grants pending from from Abbott, AMGEN, BMS, Eisai, and Savient Pharmaceuticals.

Charles Turck, PharmD is an officer and part owner of ScientiaCME, LLC. ScientiaCME has received grants from Bayer, Edwards Lifesciences, Eisai, Daiichi-Sankyo, Lilly, Merck, Pfizer, Sanofi Aventis, Wolf-Torey Medical, and currently has grants pending from from Abbott, AMGEN, BMS, Eisai, and Savient Pharmaceuticals.

Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. ScientiaCME and Educational Review Systems do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the opinions of ScientiaCME and/or Educational Review Systems . Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Dr. Boomershine discloses that unapproved drug use is discussed for tapentadol, paroxetine, cyclobenzaprine, mirtazepine, trazodone, tramadol, fluoxetine, amitriptyline, gabapentin, modafinil, methylphenidate, dexmethylphenidate, dextroamphetamines, atomoxetine, pramipexole, ropinirole, carbidopa-levodopa, sodium oxybate, quetiapine, venlafaxine, armodafinil, acetaminophen.

Commercial Support Disclosure: This program is supported by an educational grant from Pfizer, Inc.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Optionally, download and print the workbook so that you can take notes during the presentations

View the on-line program. You may view this is more that one session, and may pause or repeat any portion of the presentation if you need to.

Take the post-test

Complete the program evaluation and CE registration/attendance verification. A CE certificate will be emailed to you within 30 days upon receipt of a completed activity evaluation form and a completed posttest.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest. AAFP / ACCME has no score requirement for the post test. Your statement of credit will be issued to you within 30 days of completion of this on-line program.